We aim to get in touch within one business day
Disclaimer: I consent to my data being processed for the purpose of responding to my inquiry and in accordance with the Roche Global Privacy Policy & Privacy Notice for Pharmacovigilance
Bring the potential of ROZLYTREK® to life
ROZLYTREK:
A potent ROS1 and TRK inhibitor1
ROZLYTREK: A potent ROS1 and TRK inhibitor1
ROZLYTREK indications1
ROZLYTREK as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with solid tumours, expressing a NTRK gene fusion,
ROZLYTREK as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors.
ROZLYTREK inhibits TRK and ROS1 kinases, preventing the hyperactivation of downstream signalling pathways that lead to unconstrained cell proliferation1
A potent, selective TRK and ROS1 inhibitor, demonstrating antitumour activity within the CNS1
CNS metastases are associated with significant morbidity and poor survival8
Proven efficacy in the CNS in ROS1+ NSCLC
Proven efficacy in the CNS in NTRK fusion+ solid tumours
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
CNS, central nervous system; MAPK, mitogen-activated protein kinase; P13K-AKT,phosphatidylinositol 3-kinase-protein kinase B; NTRK, neurotrophic tyrosine receptor kinase; NSCLC, non-small cell lung cancer; PLC(gamma)-PKC, phospholipase C-protein kinase C; P-gp, permeability-glycoprotein; ROS1, c-ros oncogene 1; TRK, tyrosine receptor kinase.
References